Johnson & Johnson’s forecast aligns with GlobalData’s analyst consensus, which projects $49 billion in global sales by 2030.
The company is bolstering its pipeline with deals such as the December 2025 acquisition of Halda Therapeutics for $3.05 billion in cash. Halda’s lead asset, HLD-0915, now in Phase II, could strengthen J&J’s long-term position in prostate cancer.
J&J’s CEO said the company still has an appetite for “small acquisitions” aimed at identifying early-stage assets with the potential to generate major sales with J&J’s backing. Based on the evidence presented by the CEO, the company’s optimistic oncology portfolio forecast appears reasonable.
Sign up to receive daily updates on the latest healthcare industry trends emerging from the JP Morgan Healthcare Conference 2026.
Sign up to receive a comprehensive report after the conference.
“JPM26: J&J reveals oncology strategy” was originally created and published by Pharmaceutical Technology, a GlobalData-owned brand.
Leave a Reply